Pale Fire Capital SE boosted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 84.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,716,328 shares of the biotechnology company’s stock after buying an additional 1,246,673 shares during the quarter. Heron Therapeutics accounts for 0.2% of Pale Fire Capital SE’s investment portfolio, making the stock its 26th biggest position. Pale Fire Capital SE’s holdings in Heron Therapeutics were worth $2,173,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in HRTX. Advisory Services Network LLC increased its holdings in Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after buying an additional 18,114 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics during the second quarter worth $26,000. R Squared Ltd acquired a new stake in Heron Therapeutics in the first quarter valued at $27,000. SG Americas Securities LLC lifted its stake in Heron Therapeutics by 39.1% in the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 6,858 shares during the last quarter. Finally, HORAN Wealth LLC acquired a new stake in Heron Therapeutics in the first quarter valued at $33,000. 80.01% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on HRTX. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Needham & Company LLC downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Wall Street Zen downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reduced their price target on Heron Therapeutics to $2.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Zacks Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.50.
Heron Therapeutics Trading Down 0.7%
Shares of Heron Therapeutics stock opened at $0.46 on Friday. The business has a fifty day simple moving average of $0.53 and a two-hundred day simple moving average of $0.90. Heron Therapeutics, Inc. has a 1 year low of $0.38 and a 1 year high of $1.93. The company has a market capitalization of $86.27 million, a price-to-earnings ratio of -2.53 and a beta of 1.65. The company has a debt-to-equity ratio of 17.51, a current ratio of 2.53 and a quick ratio of 1.51.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million for the quarter, compared to the consensus estimate of $36.72 million. Research analysts forecast that Heron Therapeutics, Inc. will post -0.09 EPS for the current year.
About Heron Therapeutics
Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.
Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.
Read More
- Five stocks we like better than Heron Therapeutics
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
